(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...

Patients with MDS report more symptoms than physicians, indicating a communication gap in symptom assessment. Allogeneic hematopoietic stem cell transplantation is the only cure but is limited to ...

In patients with high-risk myelodysplastic syndromes, hypomethylating agents are underutilized, particularly among older, female and non-White patients. Among patients with high-risk myelodysplastic ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS). However, most of what scientists know about the impact of ...

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of ...

Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...